Immunopharmacology

Front 1

moa of corticosteroids

Back 1

decrease prostaglandins, leukotrienes, cytokines, and PAF

inhibit proliferation of T cells

dampen humoral immunity (decreases IgG)

induces apoptosis in immune cells

Front 2

toxicity of corticosteroids

Back 2

adrenal suppression

growth inhibition

muscle wasting

osteoporosis

salt retention

diabetes

psychoses

Front 3

MOA of cyclosporine

Back 3

binds cyclophilin and blocks differentiation and activation of T cells by inhibiting calcineurin

prevents production of IL-2

Front 4

effects of blocking calcineurin

Back 4

can't get to nucleus to transcribe IL-2 or 3 or IFN-G

Front 5

use of cyclosporine

Back 5

supresses organ rejection, AI disorders

Front 6

toxicity of cyclosporine

Back 6

viral infections

lymphoma

nephrotoxic (give mannitol)

GVHD

Front 7

MOA of tacrolimus

Back 7

binds FK binding protein and inhibits calcineurin

Front 8

MOA of sirolimus

Back 8

inhibits T cell response to cytokines (IL-2), inhibits B cell proliferation

Front 9

toxicity of tacrolimus

Back 9

nephotoxic, peripheral neuropathy, HTN, pleural effusion, hyperglycemia, cholelithiasis

Front 10

toxicity of sirolimus

Back 10

hyperlipidemia, thrombocytopenia, leukopenia, hepatoxic, diarrhea

Front 11

MOA of azathioprine

Back 11

precursor of 6-MP that interferes with the metabolism and synthesis of nucleic acids

toxic to proliferating lymphocytes

Front 12

toxicity of azathioprine

Back 12

bone marrow suppression

metabolized via xanthine oxidase (no allopurinol)

carcinogenic

Front 13

MOA of muromonab-CD3

Back 13

monoclonal antibody that binds to CD3 on surface of T cells

blocks cellular interaction owith CD3 protein responsible for T cell signal transduction

blocks cytotoxic t cell activity

Front 14

use of muromonab

Back 14

renal rejection crisis

Front 15

MOA of mycophenolate mofetil

Back 15

inhibits de novo guanine synthesis and blocks lymphocyte production (can't get into alternative pathway)

Front 16

use for mycophenolate

Back 16

solid organ transplants

Front 17

MOA of cyclophosphamide

Back 17

cytotoxic to proliferating B cells, though some T as well

Front 18

use for cyclophosphamide

Back 18

hemolytic anemia, red cell aplasia, bone marrow transplants

Front 19

MOA of etnercept

Back 19

recombinant TNF receptor that binds TNF-A and decreases formation of IL and adhesion molecules in leukocyte activation

Front 20

use for etancercept

Back 20

RA

Front 21

MOA of thalidomide

Back 21

suppresses TNF production

Front 22

uses for thalidomide

Back 22

treats aphthous ulcers and wasting syndrome in AIDS

Front 23

MOA of leflunomide

Back 23

inhibits dihyro-orotic acid dehydrogenase (ribonucleotide synthesis) arrests lymphocytes in G1 phase

Front 24

use of leflunomide

Back 24

RA

Front 25

MOA of alefacept

Back 25

tragets CD2 receptor on surface of T cells

Front 26

use for alefacept

Back 26

treats psoriasis

Front 27

MOA of daclizumab

Back 27

MCA with affinicty for IL-2 receptor on activated T cells

Front 28

MOA of aldesleukin

Back 28

recombinant IL-2, promotes production of cytotoxic T cells and activates NK cells

Front 29

uses of aldesleukin

Back 29

AIDS, renal carcinoma, melanoma

Front 30

MOA of filgrastim

Back 30

Granulocyte colony stimulating factor

Front 31

MOA of sargramostim

Back 31

granulocyte macrophage colongy stimulating factor

Front 32

uses for alpha IFN

Back 32

hep B/C

Kaposi

leukemia

melanoma

Front 33

use for beta IFN

Back 33

MS

Front 34

use for gamma IFN

Back 34

chronic granulomatous disease

Front 35

use for oprelvekin (IL-11)

Back 35

thrombocytopenia